A role for FOXO1 in BCR–ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia

A role for FOXO1 in BCR–ABL1-independent tyrosine kinase inhibitor resistance in chronic myeloid leukemia

Chronic myeloid leukemia (CML) patients who relapse on imatinib due to acquired ABL1 kinase domain mutations are successfully treated with second-generation ABL1-tyrosine kinase inhibitors (ABL-TKIs) such as dasatinib, nilotinib or ponatinib. However, ~40% of relapsed patients have uncharacterized B...

Full description

Bibliographic Details
Main Authors: Wagle, M, Eiring, A M, Wongchenko, M, Lu, S, Guan, Y, Wang, Y, Lackner, M, Amler, L, Hampton, G, Deininger, M W, O'Hare, T, Yan, Y
Format: Online
Language:English
Published: Nature Publishing Group 2016
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4935980/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4935980/

Similar Items